SciSparc announced that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder, or ASD, at the Soroka Medical Center in Israel. The company’s goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- SciSparc Ltd. Grants Exclusive License to Polyrizon
- SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
- SciSparc signs exclusive patent license agreement with Polyrizon
- SciSparc Advances Merger With AutoMax Motors
- SciSparc Updates Regarding the Status of the AutoMax Merger